Cargando…
CAR-NK Cells in the Treatment of Solid Tumors
CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy against hematological malignancies, the treatment is far from flawless. Its greatest drawbacks arise from a challenging...
Autores principales: | Wrona, Ewa, Borowiec, Maciej, Potemski, Piotr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197981/ https://www.ncbi.nlm.nih.gov/pubmed/34072732 http://dx.doi.org/10.3390/ijms22115899 |
Ejemplares similares
-
Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer
por: Wrona, Ewa, et al.
Publicado: (2021) -
Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours
por: White, Lydia G., et al.
Publicado: (2022) -
New Strategies for the Treatment of Solid Tumors with CAR-T Cells
por: Zhang, Hao, et al.
Publicado: (2016) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021) -
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
por: Chen, Qiuqiang, et al.
Publicado: (2022)